Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Investor webcast on Tuesday, October 10th at 8:00 a.m. ET to present clinical data.
Akero Therapeutics (AKRO) will hold an investor conference . . .
This content is for paid subscribers.
Impacting News
October 9, 2023
